Denis Larsimont

38.0k total citations · 5 hit papers
276 papers, 12.8k citations indexed

About

Denis Larsimont is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Denis Larsimont has authored 276 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 160 papers in Oncology, 106 papers in Cancer Research and 65 papers in Molecular Biology. Recurrent topics in Denis Larsimont's work include Breast Cancer Treatment Studies (71 papers), HER2/EGFR in Cancer Research (50 papers) and Cancer Genomics and Diagnostics (39 papers). Denis Larsimont is often cited by papers focused on Breast Cancer Treatment Studies (71 papers), HER2/EGFR in Cancer Research (50 papers) and Cancer Genomics and Diagnostics (39 papers). Denis Larsimont collaborates with scholars based in Belgium, France and Italy. Denis Larsimont's co-authors include Martine Piccart, Christos Sotiriou, Fátima Cardoso, Christine Desmedt, Angelo Di Leo, Mauro Delorenzi, Marianne Paesmans, Benjamin Haibe‐Kains, Virginie Durbecq and Marc Buyse and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Denis Larsimont

267 papers receiving 12.6k citations

Hit Papers

Gene Expression Profiling in Breast Cancer: Understanding... 2005 2026 2012 2019 2006 2007 2008 2007 2005 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis
    2006 1.5k citations Christos Sotiriou, Pratyaksha Wirapati et al. profile →
  2. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
    2007 724 citations Fátima Cardoso, Virginie Durbecq et al. profile →
  3. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
    2008 601 citations Christine Desmedt, Benjamin Haibe‐Kains et al. Clinical Cancer Research profile →
  4. Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade
    2007 599 citations Benjamin Haibe‐Kains, Christine Desmedt et al. Journal of Clinical Oncology profile →
  5. Identification of molecular apocrine breast tumours by microarray analysis
    2005 585 citations Denis Larsimont, Mauro Delorenzi et al. profile →

Peers

Denis Larsimont
Nobuyuki Arima Japan
Sunil Badve United States
Samuel Leung Canada
Aleix Prat Spain
Reiki Nishimura Japan
Tomofumi Osako Japan
Yasuo Toyozumi Japan
Rumiko Tashima Japan
Anne Vincent‐Salomon France
Yasuyuki Nishiyama Japan
Nobuyuki Arima Japan
Denis Larsimont
Citations per year, relative to Denis Larsimont Denis Larsimont (= 1×) peers Nobuyuki Arima

Countries citing papers authored by Denis Larsimont

Since Specialization
Citations

This map shows the geographic impact of Denis Larsimont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Larsimont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Larsimont more than expected).

Fields of papers citing papers by Denis Larsimont

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Larsimont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Larsimont. The network helps show where Denis Larsimont may publish in the future.

Co-authorship network of co-authors of Denis Larsimont

This figure shows the co-authorship network connecting the top 25 collaborators of Denis Larsimont. A scholar is included among the top collaborators of Denis Larsimont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Larsimont. Denis Larsimont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Venet, David, Ghizlane Rouas, Xiaoxiao Wang, et al.. (2024). Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer.. Journal of Clinical Oncology. 42(16_suppl). e12576–e12576. 2 indexed citations
3.
Amato, Ottavia, Laurence Buisseret, Géraldine Gebhart, et al.. (2023). PIK3CAcopy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. Molecular Case Studies. 9(2). a006255–a006255. 5 indexed citations
4.
Bohlok, Ali, François Richard, Valério Lucidi, et al.. (2023). Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers. Frontiers in Oncology. 13. 1260880–1260880. 4 indexed citations
5.
Moreau, Michel, et al.. (2023). Effectiveness of Carbon Localization for Invasive Breast Cancer: An Institutional Experience. The Breast Journal. 2023. 1–9.
6.
Agostinetto, Elisa, Matteo Lambertini, Françoise Rothé, et al.. (2022). Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology. 6(6). e2200148–e2200148. 48 indexed citations
7.
Richard, François, Samira Majjaj, David Venet, et al.. (2020). Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research. 26(23). 6254–6265. 19 indexed citations
8.
Demetter, Pieter, María Gómez Galdón, Ligia Craciun, et al.. (2020). Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer. BMJ Open Gastroenterology. 7(1). e000431–e000431. 4 indexed citations
9.
Liberale, Gabriel, Sophie Vankerckhove, Fikri Bouazza, et al.. (2020). Systemic Sentinel Lymph Node Detection Using Fluorescence Imaging After Indocyanine Green Intravenous Injection in Colorectal Cancer: Protocol for a Feasibility Study. JMIR Research Protocols. 9(8). e17976–e17976. 7 indexed citations
10.
Jungels, Christiane, et al.. (2018). Retroperitoneal mixed malignant mullerian tumor : exceptional localisation and prognosis. PubMed. 39(3). 146–149. 1 indexed citations
11.
Jeschke, Jana, Martin Bizet, Christine Desmedt, et al.. (2017). DNA methylation–based immune response signature improves patient diagnosis in multiple cancers. Journal of Clinical Investigation. 127(8). 3090–3102. 110 indexed citations
12.
Azim, Hatem A., Sandeep K. Singhal, Michail Ignatiadis, et al.. (2013). Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis. PLoS ONE. 8(12). 3 indexed citations
13.
Galmarini, Carlos M., Isabelle Treilleux, Fátima Cardoso, et al.. (2008). Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. Clinical Cancer Research. 14(14). 4511–4516. 55 indexed citations
14.
Sotiriou, Christos, Benjamin Haibe‐Kains, Christine Desmedt, et al.. (2006). Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures. Breast Cancer Research and Treatment. 100. 2 indexed citations
15.
Desmedt, Christine, Virginie Durbecq, Marianne Paesmans, et al.. (2004). Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel. Cancer Research. 64. 263–263. 40 indexed citations
16.
Leo, Angelo Di, David Gancberg, Denis Larsimont, et al.. (2002). HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.. PubMed. 8(5). 1107–16. 216 indexed citations
17.
Larsimont, Denis, Angelo Di Leo, Ghizlane Rouas, et al.. (2002). HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.. PubMed. 22(4). 2485–90. 11 indexed citations
18.
Nogaret, Jean‐Marie, Dina Hertens, Isabelle Veys, Pierre Bourgeois, & Denis Larsimont. (2002). Ganglion sentinelle et cancer invasif du sein: vers une nouvelle approche chirurgicale minimaliste.. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 23(3).
19.
Cardoso, Fátima, Angelo Di Leo, Denis Larsimont, et al.. (2001). Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer. Breast Cancer Research and Treatment. 69(3). 243. 2 indexed citations
20.
Frühling, J, et al.. (1992). Preoperative Axillary Immunolymphoscintigraphy (ilsc) in Breast-cancer Patients Using a 123-iodine Labeled Monoclonal-antibody (ab). European Journal of Nuclear Medicine and Molecular Imaging. 19(8). 705–705. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nobuyuki Arima Breakdown of academic impact, for papers by Sunil Badve Breakdown of academic impact, for papers by Samuel Leung Breakdown of academic impact, for papers by Aleix Prat Breakdown of academic impact, for papers by Reiki Nishimura Breakdown of academic impact, for papers by Tomofumi Osako Breakdown of academic impact, for papers by Yasuo Toyozumi Breakdown of academic impact, for papers by Rumiko Tashima Breakdown of academic impact, for papers by Anne Vincent‐Salomon Breakdown of academic impact, for papers by Yasuyuki Nishiyama
Rankless by CCL
2026